Background
Thymosin β4 is a major actin sequestering protein in cells and can interact with G-actin[1,2]. Thymosin β4 is found in many vertebrate tissues and cells and is especially concentrated in macrophages, fibroblasts, neutrophils, and platelets, which have large pools of G-actin[3]. The main physiological role of Thymosin β4 is the regulation of actin polymerization. Thymosin β4 is also involved in angiogenesis, cell survival, cell migration and fetal development[4].
Thymosin β4 plays a crucial role in the regulation of tight junction stability and acts in cytoskeleton rearrangement, which are closely related with BBB permeability[2]. Thymosin β4 is a novel regulator for primary cilia formation and it affects ciliogenesis by regulating the expression of NPHP3 in HeLa cervical cancer cells[5]. Thymosin β4 regulates HSC activation by influencing the activity of Smoothened and GLI2, suggesting Thymosin β4 as a novel therapeutic target in liver disease[6]. Synthetic Thymosin β4 peptide increases NK cell cytotoxicity mediated by intercellular adhesion molecule-1 (ICAM-1 ) through the secretion of cytolytic granules to target cells, suggests that Thymosin β4 is a key activator of NK cell cytotoxicity[7].
Thymosin β4 enhanced wound healing in a rat full thickness wound model suggest that Thymosin β4 is a potent wound healing factor with multiple activities[1]. Thymosin β4 administration during gestation may act as a powerful fetal growth promoter, by accelerating the development of newborn organs and tissues[4].Recombinant Human Thymosin β4 significantly increased the survival rate of mice infected with MHV-A59 through inhibiting virus replication, balancing the host’s immune response, alleviating pathological damage, and promoting repair of the liver[8].
参考文献:
[1]. Malinda KM, Sidhu GS, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
[2]. Song K, Han HJ, et al. Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction. Eur J Pharmacol. 2020;869:172891.
[3]. Weber A, Nachmias VT, et al, Safer D. Interaction of thymosin beta 4 with muscle and platelet actin: implications for actin sequestration in resting platelets. Biochemistry. 1992;31(27):6179-6185.
[4]. Faa G, Piras M, et al. Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery. Eur Rev Med Pharmacol Sci. 2021;25(1):431-437.
[5]. Lee JW, Kim HS, et al. Thymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells. Sci Rep. 2019;9(1):6849. Published 2019 May 2.
[6]. Kim J, Hyun J, et al. Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling. Sci Rep. 2017;7(1):3815. Published 2017 Jun 19.
[7]. Lee HR, Yoon SY, et al. Thymosin beta 4 enhances NK cell cytotoxicity mediated by ICAM-1. Immunol Lett. 2009;123(1):72-76.
[8]. Yu R, Mao Y, et al. Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection. Mediators Inflamm. 2021;2021:9979032. Published 2021 Apr 21.
胸腺素 β4 是细胞中主要的肌动蛋白螯合蛋白，可与 G-肌动蛋白相互作用[1,2]。胸腺素 β4 存在于许多脊椎动物组织和细胞中，尤其集中在巨噬细胞、成纤维细胞、中性粒细胞和血小板中，这些细胞具有大量 G-肌动蛋白[3]。胸腺素 β4 的主要生理作用是调节肌动蛋白聚合。胸腺肽 β4 还参与血管生成、细胞存活、细胞迁移和胎儿发育[4]。
胸腺素β4在调节紧密连接稳定性和细胞骨架重排中起着至关重要的作用，与血脑屏障通透性密切相关[2]。 Thymosin β4 是一种新的初级纤毛形成调节因子，它通过调节宫颈癌细胞 NPHP3 的表达影响纤毛生成[5]。 Thymosin β4 通过影响 Smoothened 和 GLI2 的活性来调节 HSC 活化，表明 Thymosin β4 可作为肝病治疗的新靶点[6]。合成的 Thymosin β4 肽通过向靶细胞分泌细胞溶解颗粒增加由细胞间粘附分子-1 (ICAM-1 ) 介导的 NK 细胞细胞毒性，表明 Thymosin β4 是一种NK细胞细胞毒性的关键激活剂[7].
Thymosin β4 在大鼠全层伤口模型中促进伤口愈合表明 Thymosin β4 是一种具有多种活性的有效伤口愈合因子[1]。妊娠期间给予胸腺素 β4 可作为强大的胎儿生长促进剂，通过加速新生儿器官和组织的发育[4]。重组人胸腺素 β4 显着提高了感染 MHV-A59 的小鼠的存活率通过抑制病毒复制，平衡宿主免疫反应，减轻病理损伤，促进肝脏修复[8]。
Protocol
| Cell experiment [1]: |
|
Cell lines
|
hCMEC/D3 cell line
|
|
Preparation Method
|
Cells were treated with 200μM PrP (106-126) with or without Thymosin β4 and Thymosin β4 siRNA. Cell viability was determined by MTT assay and LDH assay.
|
|
Reaction Conditions
|
0.01, 0.05, 0.1, and 0.5μg/mL
|
|
Applications
|
Pretreatment of hCMEC/D3 cells with various concentrations of Thymosin β4 on 200μM PrP (106-126)-treated cells resulted in significantly increased viability in a dose-dependent (0.1, 0.5 μg/ml) manner compared to cells incubated with 200μM PrP (106-126) alone. Analysis of LDH activity in the cell culture supernatants revealed that 0.1 and 0.5μg/ml Thymosin β4 significantly inhibited 200μM PrP (106-126)-induced cytotoxicity in hCMEC/D3 cells
|
| Animal experiment [2]: |
|
Animal models
|
CD1 adult nulliparous female mice, 2-5 months
|
|
Preparation Method
|
Only 6 of 10 were pregnant. At 10:00 a.m. on day E14 and E17 of gestation mice were weighed and treated with an intraperitoneal injection of Thymosin β4. Three pregnant mice received treatment with Thymosin β4 and three mice were used as a control group. To keep the same conditions of stress, the mice of the control group underwent corresponding intraperitoneal injections of vehicle (PBS). On the day E19 of gestation, caesarean sections were performed.
|
|
Dosage form
|
6mg/kg, intraperitoneal injection
|
|
Applications
|
Thymosin β4 is capable of accelerating the development of the entire fetus and fetal organs when administered to pregnant mice in the last week of gestation. Regarding the body length at birth, newborns of Thymosin β4-treated animals showed a length always higher than the neonates of non-treated mice. In multiple organs, including heart, kidney, lungs, gut, notochord and cerebral cortex, the degree of differentiation of stem/precursor cells was accelerated by the maternal administration of Thymosin β4, leading to the appearance of a more mature organ architecture
|
|
参考文献:
[1]. Song K, Han HJ, et al. Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction. Eur J Pharmacol. 2020;869:172891.
[2]. Faa G, Piras M, et al. Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery. Eur Rev Med Pharmacol Sci. 2021;25(1):431-437.
|
没有评价数据